BCAL Diagnostics Limited (BDX) Stock Statistics & Valuation Metrics

BCAL Diagnostics Limited has a market cap or net worth of AU$24.33M. The enterprise value is AU$32.98.

BCAL Diagnostics Limited has 368,683,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

BCAL Diagnostics Limited’s return on equity (ROE) is 8.92 and return on invested capital (ROIC) is -112.57%.

The current PE Ratio of BCAL Diagnostics Limited is ―. BCAL Diagnostics Limited’s PEG ratio is 0.00.

In the last 12 months, BCAL Diagnostics Limited had revenue of 182.51K and earned -7.37M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -6.16M and capital expenditures -458.98K, giving a free cash flow of -6.62M billion.

BCAL Diagnostics Limited pays an annual dividend of ―, resulting in a dividend yield of ―

BCAL Diagnostics Limited upcoming earnings date is Sep 1, 2026, Before Open (Confirmed).

BCAL Diagnostics Limited as a current ratio of 1.36, with Debt / Equity ratio of -837.07%

In the past 12 months, BCAL Diagnostics Limited has paid -2.17M in taxes.

BCAL Diagnostics Limited EV to EBITDA ratio is -3.79, with an EV/FCF ratio of -4.97.

BCAL Diagnostics Limited has AU$1.59M in cash and marketable securities with AU$6.92M in debt, giving a net cash position of -AU$5.33M billion.

Gross margin is -292.98%, with operating margin of -5145.88%, and net profit margin of -4038.97%.

The average price target for BCAL Diagnostics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―